PTPN11 and juvenile myelomonocytic leukemia: Treatment with ZOL for the control of hypercalcemia has not always been successful [8] in a case of juvenile myelomonocytic leukemia (JMML) with PTPN11 mutation where the RAS pathway was dysregulated, this may however be due to the progression of the leukemia at the late time of treatment.